Ligand Pharmaceuticals (FRA:LGDN) Total Operating Expense: €137.6 Mil (TTM As of Mar. 2026)


FRA:LGDN Ligand Pharmaceuticals Inc FRA:LGDN
73 GF Score
Price €280.00
GF Value €155.17
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Ligand Pharmaceuticals Total Operating Expense?

Ligand Pharmaceuticals FRA:LGDN +5.26% 73 Total Operating Expense is €137.6 Mil as of Mar. 2026. GuruFocus rates FRA:LGDN with a GF Score™ of 73/100 and a GF Value™ of €155.17 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Ligand Pharmaceuticals's Total Operating Expense for the three months ended in Mar. 2026 was €26.9 Mil. Ligand Pharmaceuticals's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €137.6 Mil.

Ligand Pharmaceuticals Total Operating Expense Related Terms

Ligand Pharmaceuticals Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Ligand Pharmaceuticals's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ligand Pharmaceuticals Total Operating Expense Chart

Ligand Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 66.83 132.52 101.77 127.05 176.21

Ligand Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 71.36 30.35 49.04 31.29 26.89
FRA:LGDN
73GF Score
Ligand Pharmaceuticals Inc FRA:LGDN
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ligand Pharmaceuticals Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €137.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €137.6 Mil mean?
Ligand Pharmaceuticals (FRA:LGDN) has a Total Operating Expense of €137.6 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Ligand Pharmaceuticals and its competitors.
Is Ligand Pharmaceuticals' Total Operating Expense too high?
Ligand Pharmaceuticals' current Total Operating Expense is €137.6 Mil. Overall, Ligand Pharmaceuticals has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ligand Pharmaceuticals' Total Operating Expense compare to DFTX and CGON?
Ligand Pharmaceuticals' Total Operating Expense of €137.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Ligand Pharmaceuticals and its competitors. Ligand Pharmaceuticals's current Total Operating Expense is €137.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ligand Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ligand Pharmaceuticals (FRA:LGDN) is currently considered Significantly Overvalued. The stock's GF Value™ is €155.17, compared to a current price of €280.00 — trading 80.4% above its estimated fair value. The current Total Operating Expense is €137.6 Mil. Ligand Pharmaceuticals' overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Ligand Pharmaceuticals (FRA:LGDN), the current Total Operating Expense is €137.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ligand Pharmaceuticals (FRA:LGDN) Overvalued in 2026?

Based on GuruFocus' analysis, Ligand Pharmaceuticals stock appears to be overvalued. The current stock price of €280.00 is trading 80.4% above its estimated GF Value™ of €155.17. GuruFocus considers Ligand Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:LGDN:

  • Total Operating Expense: €137.6 Mil
  • GF Value™: €155.17 vs. price of €280.00 (80.4% above fair value)
  • GF Score™: 73/100 with 5 warning signs

No single metric tells the full story. See the FRA:LGDN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ligand Pharmaceuticals Business Description

Other Exchanges LGND:USA
Address 555 Heritage Drive, Suite 200, Jupiter, FL, USA, 33458
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
73GF Score

Get the complete analysis for FRA:LGDN

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€280.00
Price
€155.17
GF Value